SCHEMBL7708353

SCHEMBL7708353

CC1=C(N)Nc2cc(CN(Cc3ccc(F)cc3)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
KCNQ4 P56696 3/20 0.36
KCNQ5 Q9NR82 3/20 0.36
NR1D1 P20393 1/20 0.34
NR3C2 P08235 1/20 0.33
KDM1A O60341 3/20 0.33
LMNA P02545 2/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
RIPK1 Q13546 2/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711366 0.92 HDAC1 (0.37) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7708189 0.92 HDAC3 (0.37) HDAC3HDAC1HDAC2NCOR2LMNA
SCHEMBL7711248 0.92 RIPK1 (0.37) GRM2HDAC3HDAC1HDAC2NCOR2
SCHEMBL7704910 0.91 HDAC1 (0.45) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7704965 0.90 HDAC3 (0.36) HDAC3HDAC1HDAC2NCOR2NR1D1
SCHEMBL7711328 0.89 HDAC3 (0.35) HDAC3HDAC1HDAC2NCOR2TP53
SCHEMBL7704946 0.89 ALDH1A1 (0.38) HDAC3HDAC1HDAC2NCOR2NR1D1
SCHEMBL7710867 0.89 ALDH1A1 (0.38) HDAC3HDAC1HDAC2NCOR2LMNA
SCHEMBL7710748 0.88 CA2 (0.35) HDAC3HDAC1HDAC2NCOR2KDM4E
SCHEMBL7713435 0.88 HDAC1 (0.34) HDAC3HDAC1HDAC2NCOR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed